Table 1 The baseline clinical characteristics of enrolled patients with stage IB3/IIA2-IVA cervical adenocarcinoma before and after PSM
Clinical parameters | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
Primary RT (N = 1061) | Surgery + PORT (N = 302) | p-value | Primary RT (N = 396) | Surgery + PORT (N = 198) | p-value | |
Age, years (range) | 50 (21–96) | 46 (22–88) |  < 0.001* | 50 (24–95) | 48 (22–88) | 0.104 |
Race | Â | Â | 0.162 | Â | Â | 0.600 |
 Black | 87 (8.20%) | 15 (4.97%) |  | 28 (7.07%) | 11 (5.56%) |  |
 White | 835 (78.70%) | 244 (80.79%) |  | 304 (76.77%) | 159 (80.30%) |  |
 Others or Unknown | 139 (13.10%) | 43 (14.24%) |  | 64 (16.16%) | 28 (14.14%) |  |
Year of diagnosis | Â | Â | 0.027* | Â | Â | 0.476 |
 2004–2008 | 282 (26.58%) | 97 (32.12%) |  | 94 (23.74%) | 56 (28.28%) |  |
 2009–2013 | 362 (34.12%) | 111 (36.75%) |  | 150 (37.88%) | 72 (36.36%) |  |
 2014–2017 | 417 (39.30%) | 94 (31.13%) |  | 152 (38.38%) | 70 (35.35%) |  |
Tumor size, mm |  |  |  < 0.001* |  |  | 0.134 |
 <  = 40 | 274 (25.82%) | 153 (50.66%) |  | 128 (32.32%) | 66 (33.33%) |  |
 > 40, <  = 60 | 480 (45.24%) | 114 (37.75%) |  | 179 (45.20%) | 101 (51.01%) |  |
 > 60 | 307 (28.93%) | 35 (11.59%) |  | 89 (22.47%) | 31 (15.66%) |  |
Grade |  |  |  < 0.001* |  |  | 0.122 |
 Well differentiated | 137 (12.91%) | 52 (17.22%) |  | 71 (17.93%) | 35 (17.68%) |  |
 Moderately differentiated | 339 (31.95%) | 139 (46.03%) |  | 162 (40.91%) | 82 (41.41%) |  |
 Poorly differentiated | 251 (23.66%) | 80 (26.49%) |  | 80 (20.20%) | 54 (27.27%) |  |
 Undifferentiated; anaplastic | 47 (4.43%) | 12 (3.97%) |  | 27 (6.82%) | 11 (5.56%) |  |
 Unknown | 287 (27.05%) | 19 (6.29%) |  | 56 (14.14%) | 16 (8.08%) |  |
FIGO stage |  |  |  < 0.001* |  |  | 0.925 |
 IB3/IIA2-IIB | 573 (54.01%) | 104 (34.44%) |  | 192 (48.48%) | 99 (50.00%) |  |
 III | 464 (43.73%) | 195 (64.57%) |  | 198 (50.00%) | 96 (48.48%) |  |
 IIIA | 27 (2.54%) | 2 (0.66%) |  | 5 (1.26%) | 2 (1.01%) |  |
 IIIB | 75 (7.07%) | 1 (0.33%) |  | 23 (5.81%) | 1 (0.51%) |  |
 IIIC | 351 (33.08%) | 189 (62.58%) |  | 168 (42.42%) | 90 (45.45%) |  |
 III, NOS | 11 (1.04%) | 3 (0.99%) |  | 2 (0.51%) | 3 (1.52%) |  |
 IVA | 24 (2.26%) | 3 (0.99%) |  | 6 (1.52%) | 3 (1.52%) |  |
T stage |  |  |  < 0.001* |  |  | 0.235 |
 T1 | 338 (31.86%) | 167 (55.30%) |  | 155 (39.14%) | 77 (38.89%) |  |
 T2 | 512 (48.26%) | 115 (38.08%) |  | 179 (45.20%) | 101 (51.01%) |  |
 T3 | 187 (17.62%) | 17 (5.63%) |  | 56 (14.14%) | 17 (8.59%) |  |
 T4 | 24 (2.26%) | 3 (0.99%) |  | 6 (1.52%) | 3 (1.52%) |  |
N stage |  |  |  < 0.001* |  |  | 0.482 |
 N0 | 696 (65.60%) | 113 (37.42%) |  | 228 (57.58%) | 108 (54.55%) |  |
 N1 | 365 (34.40%) | 189 (62.58%) |  | 168 (42.42%) | 90 (45.45%) |  |
Chemotherapy | Â | Â | 0.015* | Â | Â | 0.593 |
 No | 126 (11.88%) | 52 (17.22%) |  | 67 (16.92%) | 37 (18.69%) |  |
 Yes | 935 (88.12%) | 250 (82.78%) |  | 329 (83.08%) | 161 (81.31%) |  |